Idiopathic Pulmonary Fibrosis — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Evaluating prognostic value of the prognostic nutritional index, CRP-to-albumin ratio and lymphocyte-to-CRP ratio in patients with idiopathic pulmonary fibrosis.
Zhang Qing et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42363640/
- 2.
Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Kim Kyeongmin et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42339520/
- 3.
Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE).
Lang David et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41852279/
- 4.
Multi-omics reveals the effects and mechanisms of Xinxue Granules against idiopathic pulmonary fibrosis through activating the cAMP/EPAC/CREB axis.
Zhang Xia et al. — Journal of ethnopharmacology (15 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42302945/
- 5.
Ophiopogon japonicus alleviates pulmonary fibrosis through modulation of HIF1A/TUBB3 axis-associated M2 macrophage polarization and arginine metabolic alterations.
Wen Kehan et al. — Journal of ethnopharmacology (15 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42285238/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
Recruiting — Na — University of Sydney
https://clinicaltrials.gov/study/NCT06122233
- 2.
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Recruiting — Phase 2 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07036523
- 3.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting — Phase 3 — United Therapeutics
https://clinicaltrials.gov/study/NCT05943535
- 4.
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting — Phase 2 — Mediar Therapeutics
https://clinicaltrials.gov/study/NCT06967805
- 5.
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
Recruiting — Phase 2 — Avalyn Pharma Inc.
https://clinicaltrials.gov/study/NCT07194382
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The cause is unknown and it predominantly affects adults over 50. Three antifibrotic medicines can slow progression, and research into new treatments is advancing rapidly. An estimated 8,500 Australians live with IPF.
Most Recent Research
BACKGROUND: The clinical outcome of patients with idiopathic pulmonary fibrosis (IPF) exhibit significant variability. Inflammation, immune response, and nutritional status are critical factors influencing the progression of IPF. Consequently, the identification of biomarkers that integrate these three elements is essential for evaluating prognosis and optimizing treatment strategies in IPF patients. METHODS: We analyzed and compared baseline data from 240 IPF patients at the Second Xiangya Hospital of Central South University, covering the period from January 2011 to December 2020. Correlation analyses were conducted to assess the relationship between the prognostic nutritional index (PNI), C-reactive protein (CRP) to albumin ratio (CAR) and lymphocyte to CRP ratio (LCR) with pulmonary function, age, and body mass index (BMI). The predictive accuracy of PNI, CAR and LCR was assessed using Kaplan-Meier survival curves, receiver operating characteristic (ROC) curves, and calibration curves. Potential risk factors were identified through Cox regression analysis. RESULTS: Non-survivors and IPF-related deaths exhibited lower PNI and LCR and higher CAR compared to survivors. PNI demonstrated the strongest correlation with age and BMI, while LCR was most strongly correlated with pulmonary function. In terms of predictive ability, PNI outperformed CAR and LCR for both overall and IPF-related mortality. Univariate Cox regression analyses indicated that PNI, CAR, and LCR effectively discriminated between overall survival (OS) and IPF-related mortality. However, in multivariate analyses, PNI remained the sole independent predictor of OS and IPF-related mortality. CONCLUSION: PNI serves as a robust prognostic indicator for OS and IPF-related mortality in patients with IPF, demonstrating superior predictive capability compared to CAR and LCR.
Common Questions
What is Idiopathic Pulmonary Fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease in which scar tissue builds up in the lungs, making breathing increasingly difficult. The cause is unknown and it predominantly affects adults over 50. Three antifibrotic medicines can slow progression, and research into new treatments is advancing rapidly. An estimated 8,500 Australians live with IPF.
How many clinical trials are available for Idiopathic Pulmonary Fibrosis?
RareWays currently indexes 697 clinical trials for Idiopathic Pulmonary Fibrosis, of which 126 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Idiopathic Pulmonary Fibrosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Idiopathic Pulmonary Fibrosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.